What GSK Canada does

GSK Canada (legal entity GlaxoSmithKline Inc.) is the wholly-owned Canadian operating subsidiary of UK-listed GSK plc, headquartered in Mississauga, Ontario with divisional offices in Montréal and Québec City and a Ste-Foy vaccine manufacturing facility. The company operates as a research-based biopharmaceutical business employing approximately 1,629 full-time staff across Canada and reporting FY2024 sales of approximately $1.05 billion. Its portfolio spans three categories: specialty medicines (oncology assets Blenrep, Jemperli, Ojjaara, Zejula; immunology/respiratory biologics Benlysta, Nucala, Exdensur), vaccines (Shingrix, Arexvy, Bexsero, Boostrix, Cervarix, FluLaval Tetra, and others), and general medicines (Advair, Trelegy Ellipta, Ventolin, Valtrex, plus the Stiefel dermatology line). The company also operates ViiV Healthcare in Canada as a majority-owned HIV-focused subsidiary with Pfizer and Shionogi as minority shareholders.

The underlying technology base rests on proprietary adjuvant systems (AS01E/AS01B used in Shingrix and Arexvy), the ELLIPTA dry powder inhaler platform across multiple respiratory brands, and an R&D approach that combines human genetics, functional genomics, AI/ML, and the Microsoft Discovery agentic AI platform to identify drug targets and design new molecules across respiratory, immunology, oncology, HIV, and infectious diseases. Manufacturing is anchored by the Ste-Foy facility, which produces a significant share of Canada's seasonal influenza vaccine supply and serves as the domestic source for pandemic influenza vaccine requirements.

GSK Canada generates revenue through prescription pharmaceutical product sales reimbursed via a hybrid of public channels (pCPA pan-Canadian negotiations, provincial formularies such as RAMQ in Quebec), private payers, and dedicated patient support programs (MyMoment, Vista, Monarch, Jemperli, Horizon, Zejula). The go-to-market combines enterprise field sales to healthcare professionals, HCP self-serve portals (GSKPro, GSK Medical), pharmacy network partnerships (Innovicares, Valtrex One), and direct distribution through wholesalers and the Ste-Foy manufacturing site. Customers include physicians, specialists, hospitals, pharmacists, and provincial health authorities, with patient advocacy organizations funded through grants as part of stakeholder engagement.

Name

GSK Canada

Legal name

GlaxoSmithKline Inc.

Website

https://ca.gsk.com

Company type

Private

Founded year

1902

Operating status

Operating

Short description

GSK Canada is the wholly-owned Canadian subsidiary of GSK plc, selling specialty medicines, vaccines, and general medicines across oncology, respiratory, HIV, and infectious diseases, generating approximately $1.05 billion in 2024 revenue through prescription and public reimbursement channels.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

Keywords

• Prescription pharmaceuticals
• Vaccine manufacturing
• Specialty medicines
• Respiratory therapeutics
• Oncology biologics

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Vaccines, Specialty Medicines, General Medicines): Primary revenue from sales of prescription medicines, vaccines, and consumer health products across Canada. 2024 GSK in Canada Sales: $1,054,949,000. Total Payments to HCPs and HCOs represent 2.03% of Sales.
2. Specialty Medicines Sales: Revenue from specialty medicines including oncology products (Blenrep, Jemperli, Ojjaara, Zejula), immunology/respiratory products (Benlysta, Nucala, Exdensur), and Flolan.
3. Vaccine Sales: Revenue from vaccines including Shingrix, Arexvy (RSV), Boostrix, Bexsero, Cervarix, Engerix-B, FluLaval Tetra, Havrix, Infanrix-Hexa, Menjugate Liquid, Menveo, Priorix, Rotarix, Synflorix, Twinrix, Varilrix, Arepanrix H5N1, Flulaval Tetra, Fluviral, Priorix-Tetra.
4. General Medicines Sales: Revenue from general medicines including Advair, Anoro Ellipta, Arnuity Ellipta, Avamys, Avodart, Breo Ellipta, Clavulin, Flolan, Flovent, Imitrex, Incruse Ellipta, Jalyn, Lamictal, Malarone, Mepron, Parnate, Paxil, Relenza, Serevent, Trelegy Ellipta, Valtrex, Ventolin, Volibris, and Stiefel dermatology products (Clindoxyl, Stieprox, Stieva-A).

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Core offering

GSK Canada researches, develops, manufactures, and commercializes prescription pharmaceuticals and vaccines in Canada across three product pillars: Specialty Medicines (oncology and immunology/respiratory biologics such as Blenrep, Jemperli, Ojjaara, Zejula, Benlysta, Nucala, Exdensur), Vaccines (including adjuvanted vaccines Shingrix and Arexvy, plus paediatric and adult immunizations), and General Medicines (respiratory, dermatology, anti-infective and primary care products including the Ellipta inhaler family, Ventolin, Advair, Valtrex, Malarone, Paxil, and Stiefel dermatology brands). The company supports access via patient support programs, public reimbursement negotiations, and HCP-focused portals, and operates the Ste-Foy Vaccine Production Facility in Quebec that supplies Canada's seasonal and pandemic influenza vaccines.

Product overview

GSK Canada's portfolio is organized across three product categories: Specialty medicines, Vaccines, and General medicines. The Specialty medicines portfolio focuses on oncology and respiratory/immunology, including BLENREP (multiple myeloma), JEMPERLI (endometrial cancer), OJJAARA (myelofibrosis), ZEJULA (ovarian cancer), BENLYSTA (lupus), EXDENSUR (severe asthma), and NUCALA (COPD/severe asthma). The Vaccines portfolio is one of the broadest in the industry and includes SHINGRIX (shingles), AREXVY (RSV), BEXSERO (meningococcal B), BOOSTRIX (Tdap), CERVARIX (HPV), ENGERIX-B, HAVRIX, MENVEO, PRIORIX (MMR), TWINRIX (Hep A/B), VARILRIX, FLULAVAL Tetra, and pediatric vaccines. The General medicines portfolio covers respiratory therapies (ADVAIR, ANORO ELLIPTA, BREO ELLIPTA, FLOVENT, INCRUSE ELLIPTA, SEREVENT, TRELEGY ELLIPTA, VENTOLIN), anti-infectives (CLAVULIN, MALARONE, VALTREX), and additional treatments. The Stiefel Dermatology line (CLINDOXYL, STIEPROX, STIEVA-A) adds specialized dermatology products. GSK Canada's R&D is supported by a Ste-Foy vaccine manufacturing facility in Québec that produces Canada's seasonal influenza vaccine and pandemic influenza vaccine requirements.

Differentiator

Problem solved

Functional benefit

Brands

• Stiefel: A world-leading specialist dermatology business with innovative products, described as 'Stiefel, a GSK company', offering products like CLINDOXYL, STIEPROX, and STIEVA-A in Canada.
• ViiV Healthcare

Products and services

• BENLYSTA (belimumab) A specialty biologic medicine for the treatment of systemic lupus erythematosus (lupus), targeting B-lymphocyte stimulator (BLyS). Supported by the Monarch Patient Support Program.
• BLENREP (belantamab mafodotin) An antibody-drug conjugate approved in Canada as combination therapy for relapsed/refractory multiple myeloma. Supported by the MyMoment Patient Support Program. pCPA negotiations initiated May 2026.
• EXDENSUR (depemokimab) A long-acting anti-IL-5 monoclonal antibody approved by Health Canada on June 16, 2026 for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps.
• JEMPERLI (dostarlimab) A PD-1 inhibitor (anti-PD-1 monoclonal antibody) approved for primary advanced or first recurrent endometrial cancer in combination with chemotherapy. Supported by the Jemperli Patient Support Program. Quebec RAMQ public reimbursement effective February 2026.
• NUCALA (mepolizumab) An anti-IL-5 monoclonal antibody approved by Health Canada on June 9, 2026 as add-on maintenance treatment for adult patients with COPD, in addition to severe asthma and other indications. Supported by the Vista Patient Support Program.
• OJJAARA (momelotinib) A JAK1/JAK2/ACVR1 inhibitor approved for myelofibrosis in adults with moderate to severe anemia. First publicly reimbursed in Quebec via RAMQ in November 2025. Supported by the MyMoment Patient Support Program.
• ZEJULA (niraparib) A PARP inhibitor for the maintenance treatment of ovarian cancer. Supported by the Zejula Patient Support Program.
• SHINGRIX (Recombinant, AS01B adjuvanted) Herpes Zoster (shingles) vaccine, non-live recombinant and AS01B adjuvanted, for adults 50 years and older.
• AREXVY (RSV vaccine, recombinant, AS01E adjuvanted) Respiratory Syncytial Virus (RSV) vaccine approved for older adults in Canada and publicly funded through prevention programs for older adults as of September 2025.
• BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) for protection against meningococcal group B disease.
• BOOSTRIX Combined diphtheria, tetanus, acellular pertussis (adsorbed) vaccine for booster vaccination (Tdap), also available as BOOSTRIX-Polio with inactivated poliomyelitis component.
• CERVARIX Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted) for cervical cancer prevention.
• ENGERIX-B Hepatitis B surface antigen (recombinant) vaccine for hepatitis B prevention.
• FLULAVAL Tetra Quadrivalent Influenza Vaccine (Split Virion, Inactivated) for seasonal influenza prevention. Shipped annually by GSK Canada from the Ste-Foy manufacturing facility.
• HAVRIX Hepatitis A virus, inactivated vaccine for hepatitis A prevention.
• MENVEO Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine for meningococcal disease prevention.
• PRIORIX Combined measles, mumps and rubella vaccine, live, attenuated (MMR). Also available as PRIORIX-Tetra with varicella.
• TWINRIX Combined hepatitis A virus (inactivated) and hepatitis B surface antigen (recombinant) vaccine.
• VARILRIX Varicella Virus Vaccine, live, attenuated (Oka-strain) for chickenpox prevention.
• ADVAIR (salmeterol, fluticasone propionate) A combination inhaler (ICS/LABA) containing salmeterol and fluticasone propionate for asthma and COPD.
• ANORO ELLIPTA (umeclidinium and vilanterol) A long-acting dual bronchodilator (LAMA/LABA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.
• BREO ELLIPTA (fluticasone furoate / vilanterol) A once-daily ICS/LABA combination inhaler for asthma and COPD maintenance treatment, delivered via the Ellipta device.
• FLOVENT (fluticasone propionate) An inhaled corticosteroid for the maintenance treatment of asthma.
• INCRUSE ELLIPTA (umeclidinium) A long-acting muscarinic antagonist (LAMA) inhaler for the maintenance treatment of COPD, delivered via the Ellipta device.
• TRELEGY ELLIPTA (fluticasone furoate / umeclidinium / vilanterol) The first single-inhaler triple therapy (ICS/LAMA/LABA) for the maintenance treatment of asthma and COPD, delivered via the Ellipta device.
• VENTOLIN (salbutamol sulphate) A short-acting beta-agonist (SABA) rescue inhaler for asthma and COPD symptoms, available as Ventolin HFA, Ventolin Diskus, Ventolin Respirator Solution, and Ventolin I.V. Infusion Solution.
• VALTREX (valacyclovir hydrochloride) An antiviral medication for the treatment of herpes simplex, herpes zoster (shingles), and chickenpox. Supported by the Valtrex One program and Innovicares.
• MALARONE (atovaquone and proguanil hydrochloride) An antimalarial medication for the prevention and treatment of malaria caused by Plasmodium falciparum.
• Stiefel Dermatology Portfolio (CLINDOXYL, STIEPROX, STIEVA-A) Stiefel (a GSK company) specialty dermatology products including Clindoxyl (clindamycin/benzoyl peroxide) for acne, Stieprox (ciclopirox olamine) for seborrheic dermatitis and dandruff, and Stieva-A (tretinoin) for acne vulgaris.

Named customers11 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

• Save the Children CanadaflagshipGTM or Marketing PartnerLong-standing partnership supporting emergency preparedness for Indigenous children, families and communities at risk of natural disasters. 11,500+ emergency backpacks assembled since 2016 across Alberta, Saskatchewan, Manitoba, Ontario, and Quebec. Aligned with GSK's global partnership with Save the Children.
• Canadian Red CrosscoreGTM or Marketing PartnerAd hoc grants provided to support recovery and relief efforts in response to natural disasters, providing support to communities where GSK employees work and live. Funds are used to provide shelter, essential items and comfort to those impacted.
• Canadian Hospice Palliative Care Association (CHPCA)coreStrategic or Co-development PartnerLong-standing supporter; GSK contributed $100,000 in 2025 to help ensure every Canadian has access to quality hospice palliative care. Over $3 million contributed over the last 20 years to support the hospice palliative care movement in Canada.
• Health Partners International Canada (HPIC)coreStrategic or Co-development PartnerFunded to improve access to medicine and healthcare to children and families living in vulnerable communities around the world.
• Second HarvestminorStrategic or Co-development PartnerEnvironmental sustainability partner; supported to reduce carbon emissions from coast to coast in Canada.
• Les ScientifinesminorStrategic or Co-development PartnerSTEM education partner in Canada, supporting equitable education in science, technology, engineering and math for underrepresented populations.
• FIRST Robotics CanadaminorStrategic or Co-development PartnerSTEM education partner in Canada, supporting equitable education in science, technology, engineering and math.
• Quebec Consortium for Drug Development (CQDM)coreStrategic or Co-development PartnerInnovation hub partner; GSK Canada works actively with CQDM to investigate new therapeutic targets as well as disruptive platforms for discovery and development.
• Innovative Medicines CanadacoreOthersCross-sectoral partner to strengthen and grow the innovation environment in Canada. GSK engages with Innovative Medicines Canada, including adherence to its Code of Ethical Practices and Voluntary Framework on Disclosure of payments to HCPs/HCOs.
• Canadian Health Policy InstituteminorOthersCross-sectoral partner; works with GSK on strengthening the innovation environment in Canada.
• Coalition for Action on Innovation in CanadaminorOthersCross-sectoral partner; works with GSK to strengthen the innovation environment in Canada.
• Conference Board of CanadaminorOthersCross-sectoral partner; works with GSK to strengthen and grow the innovation environment in Canada.
• pan-Canadian Pharmaceutical Alliance (pCPA)flagshipStrategic or Co-development PartnerNegotiation partner for public reimbursement of GSK products in Canada. Successful negotiations completed for Jemperli (Dec 2025) and Ojjaara (Nov 2025); negotiations initiated for Blenrep (May 2026); letter of intent agreed for Ojjaara (Sep 2025).
• Dalhousie University (Canadian Center for Vaccinology - CCfV)coreStrategic or Co-development PartnerCollaboration to address health equity gaps through the GSK Vaccinology and Health Equity Fellowship Award, awarded to Dr. Stephana Julia Moss in June 2025.
• Health Products Stewardship Association (HPSA)minorStrategic or Co-development PartnerGSK Canada supports the Medications and Sharps Return Programs of HPSA, providing patients with safe and convenient methods to dispose health products in an environmentally responsible way.
• ViiV HealthcareflagshipStrategic or Co-development PartnerGSK majority-owns ViiV Healthcare (with Pfizer and Shionogi as shareholders); ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV, with an ambition to end the HIV epidemic. Luis Morales serves as General Manager, ViiV Healthcare Canada on GSK Canada's leadership team.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pfizer Canada: Pfizer Canada is a direct peer as a major multinational pharmaceutical subsidiary operating in Canada across vaccines, oncology, and primary care. Both compete for pCPA reimbursement, HCP engagement, and specialty medicine market share.
• Merck Canada (MSD): Merck Canada is a direct peer operating in oncology (Keytruda), vaccines, and specialty medicines in Canada. Both companies compete for hospital and specialty pharmacy channels, pCPA negotiations, and Keytruda directly competes with Jemperli in oncology indications.
• AstraZeneca Canada: AstraZeneca Canada is a direct peer with overlapping respiratory, oncology, and vaccine franchises. Compete head-to-head in COPD/asthma biologics (e.g., Tezspire vs Nucala/Exdensur) and oncology (Imfinzi/Enhertu vs Jemperli/Blenrep).
• Novartis Canada: Novartis Canada is a direct peer with overlapping specialty medicine portfolio including oncology, respiratory, and immunology products. Both participate in pCPA negotiations for high-cost specialty therapeutics and have similar Canadian commercial infrastructure.
• Roche Canada: Roche Canada is a direct peer in oncology, respiratory, and specialty therapeutics. Compete directly in oncology indications with overlapping HER2/PD-L1 targets and have similar patient support program models for specialty drug access.
• Sanofi Canada: Sanofi Canada is a direct peer with a similar portfolio structure (specialty medicines, vaccines including flu/pediatric, and general medicines). Compete directly in vaccines (Sanofi flu vaccines vs Flulaval) and respiratory (Dupixent vs Nucala/Exdensur).
• Bristol-Myers Squibb Canada: Bristol-Myers Squibb Canada is a direct peer in oncology and specialty medicines. Compete with GSK's PD-1 inhibitor (Jemperli) through Opdivo and have overlapping interests in multiple myeloma and hematology indications.
• Johnson & Johnson Innovative Medicine Canada: Janssen (J&J Innovative Medicine) Canada is a direct peer in oncology, immunology, and pulmonary hypertension. Compete directly in multiple myeloma (Darzalex vs Blenrep combinations) and immunology (Tremfya vs Benlysta).
• AbbVie Canada: AbbVie Canada is a direct peer in immunology, oncology, and specialty therapeutics. Compete with Benlysta (lupus) through Skyrizi/Rinvoq and have overlapping interests in hematology and specialty pharmacy distribution.

Broad incumbents

• Eli Lilly Canada: Eli Lilly Canada is a broad incumbent peer in pharmaceuticals with an expanding Canadian specialty and primary care portfolio. Compete in diabetes, oncology, and immunology, and participate in pCPA negotiations for high-cost specialty therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights8 records

Customer concentration

• Xtwitter.com/gskca
• YouTubeyoutube.com/watch?v=t6UIjKdP6zY

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GSK Canada